{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:33:01Z","timestamp":1790695981906,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NCI-US-CTEP","award":["NO1-CM-62203"],"award-info":[{"award-number":["NO1-CM-62203"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ygyno.2015.04.009","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T06:01:41Z","timestamp":1429250501000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia"],"prefix":"10.1016","volume":"138","clinical-trial-number":[{"clinical-trial-number":"nct00278343","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"H.","family":"Hirte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"McGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.04.009_bb0005","first-page":"340","article-title":"Chemotherapy of advanced ovarian cancer","volume":"25","author":"McGuire","year":"1998","journal-title":"Semin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.04.009_bb0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.critrevonc.2012.09.012","article-title":"Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer","volume":"86","author":"Monk","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2015.04.009_bb0015","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.009_bb0020","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2015.04.009_bb0025","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2015.04.009_bb0030","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.04.009_bb0035","series-title":"Abstract Number: 6 European Cancer Congress","article-title":"Late breaking abstract: ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer","author":"Oza","year":"2013"},{"issue":"17","key":"10.1016\/j.ygyno.2015.04.009_bb0040","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2015.04.009_bb0045","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.04.009_bb0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3747\/co.v16i3.444","article-title":"Novel developments in angiogenesis cancer therapy","volume":"16","author":"Hirte","year":"2009","journal-title":"Curr. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2015.04.009_bb0055","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2217\/fon.12.73","article-title":"Cediranib: a VEGF receptor tyrosine kinase inhibitor","volume":"8","author":"Sahade","year":"2012","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2015.04.009_bb0060","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/JCO.2006.07.2066","article-title":"Phase I clinical study of cediranib, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors","volume":"25","author":"Drevs","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.04.009_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"10 Suppl.","key":"10.1016\/j.ygyno.2015.04.009_bb0070","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.009_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ygyno.2015.04.009_bb0080","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.009_bb0085","article-title":"Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial","author":"Ledermann","year":"2013","journal-title":"Eur. J. Cancer XX"},{"issue":"11","key":"10.1016\/j.ygyno.2015.04.009_bb0090","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomized phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2015.04.009_bb0100","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2015.04.009_bb0105","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","article-title":"Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Gotlieb","year":"2012","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.04.009_bb0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cncr.28406","article-title":"Intravenousaflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study","volume":"120","author":"Tew","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.04.009_bb0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.cco.0000245316.82391.52","article-title":"Sorafenib","volume":"18","author":"Hahn","year":"2006","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2015.04.009_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2015.04.009_bb0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","article-title":"A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma","volume":"130","author":"Herzog","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2015.04.009_bb0130","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.009_bb0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2012.07.126","article-title":"A phase II trial of sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma","volume":"7","author":"Campos","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2015.04.009_bb0140","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/annonc\/mds003","volume":"23","author":"Baumann","year":"2012","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.04.009_bb0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/annonc\/mdq357","article-title":"A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC clinical trials group study","volume":"22","author":"Biagi","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.009_bb0150","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.009_bb0155","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2015.04.009_bb0160","first-page":"LBA1","article-title":"AGO-OVAR 12: a randomized placebo-controlled GCIG\/ENGOT-intergroup phase III trial of standard frontline chemotherapy +\/\u2212 nintedanib for advanced ovarian cancer [abstract]","volume":"7","author":"Du Bois","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2015.04.009_bb0165","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/13543784.17.2.253","article-title":"Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma","volume":"17","author":"Sonpavde","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ygyno.2015.04.009_bb0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"30","key":"10.1016\/j.ygyno.2015.04.009_bb0175","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2015.04.009_bb0180","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1158\/1535-7163.MCT-10-0213","article-title":"Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1\/2-neutralizing peptibody","volume":"9","author":"Coxon","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.ygyno.2015.04.009_bb0185","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2015.04.009_bb0190","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.2013.54.7299","article-title":"Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer","volume":"32","author":"Liu","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815008288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815008288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T08:28:58Z","timestamp":1537691338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815008288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0090825815008288"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}